APA (7th ed.) Citation

Hong, J., Johnson, W. T., Kartan, S., Gonsalves, A. S., Fenkel, J. M., Gong, J. Z., & Porcu, P. (2021). Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Current Oncology, 28(6), 5067. https://doi.org/10.3390/curroncol28060426

Chicago Style (17th ed.) Citation

Hong, Jennifer, William T. Johnson, Saritha Kartan, Anitha S. Gonsalves, Jonathan M. Fenkel, Jerald Z. Gong, and Pierluigi Porcu. "Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)." Current Oncology 28, no. 6 (2021): 5067. https://doi.org/10.3390/curroncol28060426.

MLA (9th ed.) Citation

Hong, Jennifer, et al. "Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)." Current Oncology, vol. 28, no. 6, 2021, p. 5067, https://doi.org/10.3390/curroncol28060426.